Your browser doesn't support javascript.
loading
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Vissers, Maurits F J M; Heuberger, Jules A A C; Groeneveld, Geert Jan; Oude Nijhuis, Jerome; De Deyn, Peter Paul; Hadi, Salah; Harris, Jeffrey; Tsai, Richard M; Cruz-Herranz, Andres; Huang, Fen; Tong, Vincent; Erickson, Rebecca; Zhu, Yuda; Scearce-Levie, Kimberly; Hsiao-Nakamoto, Jennifer; Tang, Xinyan; Chang, Megan; Fox, Brian M; Estrada, Anthony A; Pomponio, Robert J; Alonso-Alonso, Miguel; Zilberstein, Moshe; Atassi, Nazem; Troyer, Matthew D; Ho, Carole.
Afiliação
  • Vissers MFJM; Centre for Human Drug Research, Leiden, The Netherlands.
  • Heuberger JAAC; Leiden University Medical Center, Leiden, The Netherlands.
  • Groeneveld GJ; Centre for Human Drug Research, Leiden, The Netherlands.
  • Oude Nijhuis J; Centre for Human Drug Research, Leiden, The Netherlands.
  • De Deyn PP; Leiden University Medical Center, Leiden, The Netherlands.
  • Hadi S; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Harris J; Department of Neurology and Alzheimer Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Tsai RM; Laboratory of Neurochemistry and Behavior, Department of Biomedical Sciences and Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
  • Cruz-Herranz A; PRA Health Sciences, Groningen, The Netherlands.
  • Huang F; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Tong V; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Erickson R; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Zhu Y; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Scearce-Levie K; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Hsiao-Nakamoto J; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Tang X; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Chang M; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Fox BM; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Estrada AA; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Pomponio RJ; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Alonso-Alonso M; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Zilberstein M; Denali Therapeutics Inc., South San Francisco, California, USA.
  • Atassi N; Sanofi Genzyme, Cambridge, Massachusetts, USA.
  • Troyer MD; Sanofi Genzyme, Cambridge, Massachusetts, USA.
  • Ho C; Sanofi Genzyme, Cambridge, Massachusetts, USA.
Clin Transl Sci ; 15(8): 2010-2023, 2022 08.
Article em En | MEDLINE | ID: mdl-35649245
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína Serina-Treonina Quinases de Interação com Receptores / Doença de Alzheimer / Esclerose Lateral Amiotrófica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Transl Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteína Serina-Treonina Quinases de Interação com Receptores / Doença de Alzheimer / Esclerose Lateral Amiotrófica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Transl Sci Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Holanda